文献速递白血病造血干细胞移植与细胞治疗

Quizartinib联合FLAG-IDA治疗复发或难治性急性髓系白血病:PETHEMA I-II期试验

Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial.
PubMed 文献 · Am J Hematol · 2026-06-29

FLAG-QUIDA是一项多中心1/2期研究,评估Quizartinib联合FLAG-IDA在成人首次复发或难治性AML中的疗效。1期确定2期推荐剂量为60 mg/日×14天/28天周期;2期CR/CRi率为56%,MRD阴性率38%,51%桥接移植。中位无复发生存17个月优于匹配FLAG-IDA队列的7.6个月(p=0.028)。

要点

  • Quizartinib联合FLAG-IDA的2期推荐剂量为60 mg/日,每28天周期用14天。
  • 总体CR/CRi率56%,CR/CRi+MLFS率66%,各遗传亚组间无差异。
  • 51%患者桥接异基因移植,中位无复发生存17个月,优于匹配FLAG-IDA队列。

核心结论

  • Quizartinib联合FLAG-IDA在复发或难治性AML中显示出有前景的疗效,支持未来进一步研究。

研究设计与样本

  • 多中心1/2期研究,纳入成人首次复发或难治性AML患者,1期9例、2期52例,共61例。

主要发现

  • 总体CR/CRi率为56%(n=34),CR/CRi+MLFS率为66%(n=40),各遗传亚组间无差异。
  • CR/CRi患者中38%(n=13)达到可测量残留病阴性。
  • 中位无复发生存为17个月,匹配的FLAG-IDA无Quizartinib队列为7.6个月(p=0.028);中位总生存FLAG-QUIDA队列为15.8个月,匹配队列为8.6个月(p=0.09)。

关键数值与推荐

  • 1期确定Quizartinib的2期推荐剂量为60 mg/日,每28天周期用14天。

临床怎么用

  • 对于首次复发或难治性AML成人患者,可考虑Quizartinib联合FLAG-IDA方案,并尽早评估桥接异基因移植。

局限性

  • 无安全性顾虑被提出。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Quizartinib is a tyrosine kinase inhibitor with single agent activity in patients with relapsed or refractory (R/R) acute myeloid leukemia (AML) and has demonstrated efficacy in first-line therapy when combined with intensive chemotherapy in both FLT3 ITD-negative and positive AML. The FLAG-QUIDA trial was a multicenter phase 1/2 study of quizartinib combined with FLAG-IDA in adult patients with first R/R AML. The primary objectives were to determine the recommended phase 2 dose (RP2D) in phase 1 and to establish the complete remission (CR) and CR with incomplete hematologic recovery (CRi) rates in phase 2. Nine patients were included in phase 1 and 52 in phase 2. Eighteen out of 61 (30%) patients were FLT3-ITD-positive. The RP2D of quizartinib was established at 60 mg/day for 14 days per 28-day cycle. Overall, the CR/CRi rate was 56% (n = 34), and the CR/CRi plus morphologic leukemia free state (MLFS) rate was 66% (n = 40), without differences across genetic subgroups. Measurable residual disease negativity was achieved in 38% (n = 13) of CR/CRi patients. Thirty-one patients (51%) were bridged to allogeneic stem cell transplantation after FLAG-QUIDA, 28 in CR/CRi and 3 in MLFS. Median relapse-free survival was 17 months as compared to 7.6 months in a cohort of matched patients treated with FLAG-IDA without quizartinib (p = 0.028), and median overall survival was 15.8 months in the FLAG-QUIDA cohort and 8.6 months in the matched cohort (p = 0.09). No safety concerns were raised. FLAG-IDA with quizartinib demonstrated promising efficacy in R/R AML, supporting future investigations. Trial Registration: EudraCT number: 2019-001976-12; ClinicalTrials.gov identifier: NCT04112589.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Bernal T, Zambrano Márquez J, Rodríguez-Veiga R, et al. Quizartinib in Combination With FLAG-IDA for Relapsed or Refractory Acute Myeloid Leukemia (FLAG-QUIDA): A PETHEMA Phase I-II Trial. Am J Hematol. 2026. PMID: 42374628. doi:10.1002/ajh.70424

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。